TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01045746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration A
Description: over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration b
Description: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration b
Description: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
Study: NCT03528018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REACt system
Description: The REACt system is a virtual reality-based paradigm for upper limb rehabilitation that allows for interaction of individuals with restricted movements from active responses triggered when they attempt to perform a movement. The experimental system also provides multisensory stimulation in the visual, auditory, and tactile channels, and transcranial direct current stimulation coherent to the observed movements

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Physical therapy included passive and active mobilization of the paretic upper limb. Passive range of motion exercises were provided in those segments where no active movement was detected to meticulously reproduce a range of articular movements and muscle and soft tissue elongation. In case of residual active movement capability, participants were encouraged to perform the movements with the assistance of the therapists
Study: NCT02657980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband(YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Yband(YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT03595644

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+TKI
Description: Received SBRT after three months after EGFR-TKI treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI
Description: Received EGFR-TKI treatment
Study: NCT01211925

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: distal venous arterialisation
Description: The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Aspirin
Description: 100 mg per day continuous
Study: NCT03146624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: attachment retained obturator
Description: obturator which retained by attachment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clasp retained obturator
Description: obturator which retained by clasp
Study: NCT04089033

Intervention type: PROCEDURE
Intervention: Pneumatic Retinopexy
Description: The PnR technique is performed as per the PIVOT trial under local anaesthetic. First, patients will undergo a thorough scleral-depressed peripheral retinal examination to identify all pathologic features. Second, laser retinopexy will be applied to all breaks, lattice degeneration, or both in the attached retina before gas injection. Third, breaks in the detached retina will be treated with cryotherapy before gas injection or (preferably) laser retinopexy 24 to 48 hours after gas injection, with additional laser retinopexy applied at any point per surgeon discretion. Finally, anterior chamber paracentesis will be used to express as much fluid as safely possible (generally 0.3ml), followed by intravitreal injection of 100% SF6 (ideally 0.6 ml). Patients will be positioned face down for 6 hours and then raise their head 30 degrees every hour (steam roll) and then positioned to the responsible break.

Intervention type: PROCEDURE
Intervention: Pars Plana Vitrectomy
Description: For PPV, a standard 3-port PPV (23 or 25-gauge) will be performed, including posterior hyaloid detachment, core vitrectomy and 360 peripheral vitreous shave. Subretinal fluid will be drained either through the peripheral break or through a posterior retinotomy with use of heavy liquid to assist with appropriate drainage at the discretion of the responsible surgeon. A complete air-fluid exchange will be performed. Endolaser Retinopexy or transconjunctival cryopexy will be performed to treat any retinal pathology, including lattice degeneration and breaks in the attached and detached retina. A iso-expansible concentration of SF6 or C3F8 gas will be injected at the completion of the surgery. Choice of gas will be at the discretion of the responsible surgeon. Patients will be positioned immediately face down for the first 24 hours and then according to the position of the responsible break.
Study: NCT01727739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linvatec PLLA+TCP
Description: Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linvatec PLLA
Description: Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
Study: NCT01019694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Description: Open label randomized parallel
Study: NCT00403416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic Acid
Study: NCT03404505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant Achievements
Description: Play-based intervention for caregivers and infants. The efficacy of the Infant Achievements intervention for improving communication and social behavior in infants who are at risk for communication, social, or developmental delay.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver Education (CE)
Description: Parents in the CE group will be taught about child development and well-being in their home, weekly, with a weekly follow-up phone call by trained research staff.
Study: NCT04299672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postural reconstruction
Description: Interventions are described in group descriptions
Study: NCT03043508

Intervention type: OTHER
Intervention: Chart Review
Description: Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.

Intervention type: OTHER
Intervention: Chart Review
Description: Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
Study: NCT01568333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
Study: NCT01749982

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline bitartrate + Betaine
Study: NCT03189017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICP-022
Description: The drug product is a white, round, uncoated tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The placebo is a white, round, uncoated tablet.
Study: NCT02677116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Olaratumab administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan administered IV.
Study: NCT01902641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium/Sugammadex
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
Study: NCT02677116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide administered IV.
Study: NCT02446405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LHRHA or Surgical Castration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRHA or Surgical Castration
Study: NCT00535730

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Description: 0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™
Description: 0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo (concomitant-vaccine matched)
Description: Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
Description: Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
Study: NCT00739349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Cyclosporine''
Description: Cyclosporine 0.05% Ophthalmic Cationic Emulsions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOVA22007 ''Cyclosporine''
Description: Cyclosporine 0.1% Ophthalmic Cationic Emulsions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle/placebo
Description: vehicle/placebo
Study: NCT02119507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: Single application on Day 0

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment - control
Study: NCT00754026

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of interscalene catheter for shoulder surgery
Description: Distance of interscalene catheter: 2cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of interscalene catheter for shoulder surgery
Description: Distance of interscalene catheter: 6cm
Study: NCT03576157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kilkari
Description: Kilkari is an outbound service that delivers weekly, time-appropriate audio messages about pregnancy, childbirth, and childcare directly to families on their mobile phones, starting from the second trimester of pregnancy until the child is one-year-old.
Study: NCT00430768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rAAV1-CB-hAAT
Study: NCT03728673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oral Capsules
Description: Active capsules will contain 10 mg escitalopram oxalate.
Study: NCT04192981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0084
Description: GDC-0084 in 3 + 3 dose-escalation in 3 cohorts: 45, 60, 75 mg daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy radiation
Description: 30Gy in 10 fractions
Study: NCT03390439

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd-Yap 1340nm laser
Description: Each part of the abdomen will be treated with a therapeutic modality. The ND-yap 1340-nm laser will be used in the following parameters: 90 mtz / cm2 nozzle, 90 mJ / mtz power, 2.5 Hz frequency, 3 ms pulse duration, 1 pass.
Study: NCT01902641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
Study: NCT02028260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: 200 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar appearing inert tablet
Study: NCT00606385

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection
Description: Laparoscopic or Open hepatectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection
Description: Laparoscopic or Open hepatectomy
Study: NCT02127411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Relapse Prevention
Description: The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
Study: NCT02251457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranexa is FDA approved for chronic angina
Study: NCT03390439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: In the other segment of the abdomen, the dermaroller 2.5 mm will be applied, with ten to fifteen passes in the same direction and at least four crosses in the rolling areas.
Study: NCT03568864

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low nucleotide meal
Description: The participants will consume a mixed meal (sandwich) containing a nucleotide depleted mycoprotein product (low in nucleotides)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High nucleotide meal
Description: The participants will consume a mixed meal (sandwich) containing a non nucleotide depleted mycoprotein product (high in nucleotides)
Study: NCT02654808

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal trocar
Description: The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal trocar
Description: The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard trocar
Description: A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard trocar
Description: A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas.
Study: NCT04037501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care Management
Description: A computerized Care Management System (CMS) will identify unmet needs of the informal caregiver of PwD and generates suggestions for interventions. Based on these, the treating physician develops an individualized treatment and care plan and assigns specific tasks to the care manager. Upon a home visit in the caregivers' home the care manager evaluates the need for additional tasks. Based on the complete list of tasks, the care manager initiates the implementation of respective actions. Via monthly telephone calls and optional home visits the care manager monitors the status of implementation and actively coordinates the support and care for the informal caregiver recommended intervention
Study: NCT04180618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal health wallet service for emergency situation
Description: Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personal health wallet service for emergency situation
Description: Patients(caregivers) and medical staffs will be provided the personal health wallet service and evaluate the effectiveness and satisfaction for the service.
Study: NCT01509898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water jet
Description: use of water jet for a month
Study: NCT04435665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel
Description: gel for topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel
Description: gel for topical administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NFX-179 Gel
Description: gel for topical administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: vehicle gel for topical administration